Ranolazine
- Generic Name
- Ranolazine
- Brand Names
- Aspruzyo Sprinkle, Ranexa, Ranexa (previously Latixa)
- Drug Type
- Small Molecule
- Chemical Formula
- C24H33N3O4
- CAS Number
- 95635-55-5
- Unique Ingredient Identifier
- A6IEZ5M406
- Background
Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.
- Indication
Ranolazine is indicated for the treatment of chronic angina. It can be used alone or in conjunction with nitrates, beta-blockers, angiotensin receptor blockers, anti-platelet drugs, calcium channel blockers, lipid-lowering drugs, and ACE inhibitors.
Ranolazine has also been used off-label for the treatment of certain arrhythmias, including ventricular tachycardia, however, this use is not strongly supported by scientific evidence. Ranolazine has also been studied for the treatment of acute coronary syndrome, microvascular coronary dysfunction, arrhythmia, and glycemic control, which are not yet approved indications.
- Associated Conditions
- Chronic Angina, Ventricular Arrhythmia
- Associated Therapies
- -
Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA)
- First Posted Date
- 2014-05-26
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- Emory University
- Target Recruit Count
- 26
- Registration Number
- NCT02147067
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction
- Conditions
- Pulmonary HypertensionDiastolic Left Ventricular Dysfunction
- Interventions
- First Posted Date
- 2014-05-08
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Boston University
- Target Recruit Count
- 10
- Registration Number
- NCT02133352
- Locations
- 🇺🇸
Boston University Medical Center, Boston, Massachusetts, United States
A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy
- First Posted Date
- 2014-05-08
- Last Posted Date
- 2021-04-28
- Lead Sponsor
- University Medical Centre Ljubljana
- Target Recruit Count
- 10
- Registration Number
- NCT02133911
- Locations
- 🇸🇮
Advanced Heart Failure and Transplantation Programme, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia
Ranolazine and Microvascular Angina by PET in the Emergency Department
- First Posted Date
- 2014-01-31
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- Yale University
- Target Recruit Count
- 31
- Registration Number
- NCT02052011
- Locations
- 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States
Study to Reduce Symptoms of Premature Beats With Ranolazine
- First Posted Date
- 2013-11-27
- Last Posted Date
- 2015-05-01
- Lead Sponsor
- Walter Reed National Military Medical Center
- Target Recruit Count
- 72
- Registration Number
- NCT01996618
- Locations
- 🇺🇸
Walter Reed National Military Medical Center, Bethesda, Maryland, United States
A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine
- Conditions
- Soft Tissue MetastasesStage IV Prostate CancerStage IIA Prostate CancerStage III Prostate CancerAdenocarcinoma of the ProstateStage IIB Prostate CancerBone Metastases
- Interventions
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2018-12-03
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 11
- Registration Number
- NCT01992016
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
Effects of Ranolazine and Exercise on Daily Physical Activity Trial
- Conditions
- Chronic Stable Angina
- Interventions
- First Posted Date
- 2013-09-23
- Last Posted Date
- 2017-12-12
- Lead Sponsor
- Duke University
- Target Recruit Count
- 38
- Registration Number
- NCT01948310
- Locations
- 🇺🇸
Duke Center for Living, Durham, North Carolina, United States
The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure
- Conditions
- Atrial FibrillationHeart Failure
- Interventions
- Drug: PlaceboDrug: Ranolazine
- First Posted Date
- 2013-06-26
- Last Posted Date
- 2015-07-20
- Lead Sponsor
- Intermountain Health Care, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT01887353
- Locations
- 🇺🇸
Intermountain Medical Center, Murray, Utah, United States
Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects
- Conditions
- Drug-induced Surface ECG Changes
- Interventions
- First Posted Date
- 2013-06-10
- Last Posted Date
- 2018-03-08
- Lead Sponsor
- Food and Drug Administration (FDA)
- Target Recruit Count
- 22
- Registration Number
- NCT01873950
A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2013-04-30
- Last Posted Date
- 2014-03-31
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 24
- Registration Number
- NCT01843127
- Locations
- 🇺🇸
Profil Institute for Clinical Research, Inc., Chula Vista, California, United States
🇺🇸Translational Research Institute-Florida Hospital, Orlando, Florida, United States
🇺🇸SeaView Research, Inc, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.